ChromaCode

ChromaCode is a private diagnostics company commercializing its High-Definition PCR (HDPCR™) technology, a platform that significantly expands the multiplexing capability of standard digital PCR. By using amplitude modulation and spectral encoding of standard TaqMan probes paired with its ChromaCode Cloud analytics software, the company aims to provide NGS-level genomic content with the speed, simplicity, and lower cost of PCR. Its initial focus is on oncology applications, including tumor profiling and minimal residual disease (MRD) testing, targeting a large market opportunity by enabling labs to increase throughput and margins. The company appears to be in an early revenue stage, leveraging a reagent kit and software-as-a-service business model.

High-Definition PCR (HDPCR™) platform combining proprietary chemistry (using amplitude modulation and multi-spectral encoding of standard TaqMan probes) with the ChromaCode Cloud, a cloud-based data analysis and decoding software. The instrument-agnostic platform enables extreme multiplexing (>4x conventional dPCR) on standard PCR instruments.

Competes with low-plex PCR assay providers (e.g., Bio-Rad, Qiagen, Thermo Fisher) by offering higher multiplexing, and with NGS companies (e.g., Illumina, Guardant Health) by offering a simpler, faster, lower-cost alternative for specific applications. Also competes with other advanced dPCR and multiplexing technologies.